PubRank

Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer (GeparQuinto)

Clinical Trial ID NCT00567554

PubWeight™ 28.46‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00567554

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012 4.24
2 Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 2012 4.10
3 Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 2012 2.72
4 Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis 2014 2.07
5 Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. J Clin Oncol 2015 1.99
6 Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. Oncotarget 2014 1.34
7 Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†. Ann Oncol 2014 1.06
8 Combining mTOR Inhibitors with Chemotherapy and Other Targeted Therapies in Advanced Breast Cancer: Rationale, Clinical Experience, and Future Directions. Breast Cancer (Auckl) 2013 1.02
9 The role of neoadjuvant (HER)2-targeted therapies in (HER)2-overexpressing breast cancers. Curr Oncol 2009 0.98
10 Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials. BMC Med 2014 0.96
11 Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer. Int J Breast Cancer 2012 0.92
12 Anti-vascular endothelial growth factor therapy in breast cancer. Int J Mol Sci 2014 0.89
13 The therapeutic potential of mTOR inhibitors in breast cancer. Br J Clin Pharmacol 2016 0.83
14 Soy and breast cancer: focus on angiogenesis. Int J Mol Sci 2015 0.82
15 Bevacizumab and breast cancer: current therapeutic progress and future perspectives. Expert Rev Anticancer Ther 2009 0.80
16 Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib. Jpn J Clin Oncol 2010 0.79
17 The design, synthesis and biological evaluation of conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase and microtubule inhibitors as potential antitumor agents. Bioorg Med Chem 2015 0.78
18 Are we HER-ting for innovation in neoadjuvant breast cancer trial design? Breast Cancer Res 2009 0.77
19 Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review. Breast Care (Basel) 2015 0.77
20 Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies. Ther Adv Med Oncol 2016 0.75
21 Exploratory Cost-Effectiveness Analysis of Response-Guided Neoadjuvant Chemotherapy for Hormone Positive Breast Cancer Patients. PLoS One 2016 0.75
Next 100